Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients

Annals of Hematology

Volumn 86, Issue 9, 2007, Pages 639-645

  Li, Jun Min ^a   Wang, L ^a   Shen, Y ^a   Xia, Z G ^a   Chen, Y ^a,a   Chen, Q S ^a   Zeng, X Y ^a   You, J H ^a   Qian, Y ^a   Shen, Z X ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

CHOP; DLBCL; Non Hodgkin's lymphoma; Rituximab; Survival

Indexed keywords

CHINESE DRUG; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; PHOSPHATIDYLCHOLINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; CANCER STAGING; CHILL; CHINESE; CONSTIPATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEPATITIS B; HUMAN; HYPOTENSION; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS ACTIVATION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE; VIRUS ACTIVATION;

EID: 34547604211     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0320-8     Document Type: Article

References (40)

1. Akhtar S, Maghfoor I (2002) Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med 346:1830-1831
2. Cancer Therapy Evaluation Program (1998) Common toxicity criteria, version 2.0. National Cancer Institute, Bethesda
3. Chen Y, Du H, Hu WW et al (2004) Clinicopathologic analysis and classification of 365 cases of non-Hodgkin's lymphomas according to the new WHO criteria. Chin J Diagn Pathol 11:304-307
4. Cheson BD (2002) CHOP plus rituximab - Balancing facts and opinion. N Engl J Med 346:280-282
5. Cheson BD, Horning SJ, Coiffier B et al (1999) for the NCI-sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244
6. Chuang SS, Lin CN, Li CY (2000) Malignant lymphoma in southern Taiwan according to the revised European-American classification of lymphoid neoplasms. Cancer 89:1586-1592
7. Coiffier B (1994) What treatment for elderly patients with aggressive lymphoma? Ann Oncol 5:873-875
8. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
9. Colombat P, Salles G, Brousse N et al (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106
10. Czuczman MS, Fallon A, Mohr A et al (2002) Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 29(1 Suppl 2):36-40
11. Dai MS, Chao TY, Kao WY et al (2004) Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83:769-774
12. Dang NH, Hagemeister FB, Pro B et al (2004) Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 22:4095-4102
13. Davis TA, White CA, Grillo-López AJ et al (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J Clin Oncol 17:1851
14. Dixon DO, Neilan B, Jones SE et al (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 4:295-305
15. Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
16. Grillo-Lopez AJ (2002) Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol 76:385-393
17. Guan ZZ, Yu LH, He YJ et al (1989) CHOP treatment of NHL, a report of 103 cases. Chin J Cancer 8:98-100
18. Habermann T, Weller E, Morrison V et al (2003) Phase III trial of rituximab-CHOP (R-CHOP) vs CHOP with a second randomisation to maintenance rituximab (MR) or observation in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL). Blood 102:8A
19. Haioun C, Lepage E, Gisselbrecht C et al (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030
20. Harris NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392
21. He S, Zhang JB, Zhang JG et al (2003) The WHO(1997) classification of 370 cases of malignant lymphomas. Chin J Hematol 24:519-522
22. Hochster HS, Weller E, Ryan T et al (2004) Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc Am Soc Clin Oncol 23:556
23. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon
24. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
25. Leaw SJ, Yen CJ, Huang WT et al (2004) Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 83:270-275
26. Li JM, Shen Y, Chen FY et al (2003) A multi-center clinical study of anti-CD20 monoclonal antibody in combination with CHOP regimen for treatment of diffuse large B cell lymphoma. Chin J Cancer Biother 10:157-160
27. Lin TY, Zhang HY, Huang Y et al (2005) Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China - A multi-center randomized trial. Ai Zheng 24(12):1421-1426
28. Lorand-Metze I, Pereira FG, Costa FP et al (2004) Proliferation in non-Hodgkin's lymphomas and its prognostic value related to staging parameters. Cell Oncol 26:63-71
29. McLaughlin P, Grillo-Lopez AJ, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833
30. Morrison VA, Weller EA, Habermann TM (2004) Patterns of growth factor (GF) usage and febrile neutropenia (FN) among older patients (pts) with diffuse large B-cell lymphoma (DLBCL) treated with CHOP or R-CHOP: An intergroup experience (CALGB 9793, ECOG-SWOG 4494). Blood 104:3309
31. Pfreundschuh M, Kloess M, Schmits R et al (2005) Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 106:9A
32. Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
33. Rossini F, Terruzzi E, Perego D et al (2004) Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone. Cancer 100:350-355
34. Sonneveld P, de Ridder M, van der Lelie H et al (1995) Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13:2530-2539
35. Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821-830
36. Vose JM, Link BK, Grossbard ML et al (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397
37. Wu HJ, Zhang QY, Chen DF et al (2005) Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. Ai Zheng 24:1498-1502
38. Yin HF, Li T, Li JX (2003) Retrospective analysis of 304 cases of malignant lymphomas in pathology: Study and practice of the WHO classification of lymphoid neoplasms. Zhonghua Yi Xue Za Zhi 83(18):1556-1560
39. Zhang HY, Lin TY, Jiang WQ et al (2004) Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell Non-Hodgkin's lymphoma. Chin J Cancer 23:1681-1686
40. Zhang YN, Zhou XG, Zhang SH et al (2005) Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms. Zhonghua Bing Li Xue Za Zhi 34:193-197